gp209-2M antigen

BIOLOGICAL2 trials

Sponsors

Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)

Conditions

Melanoma (Skin)

Phase 1

Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma

CompletedNCT00005633

Memorial Sloan Kettering Cancer CenterMelanoma (Skin)

Start: 1999-06-30End: 2002-06-30Updated: 2013-06-19

Phase 2

Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Metastatic Melanoma

CompletedNCT00019487

National Cancer Institute (NCI)Melanoma (Skin)

Start: 1998-11-30End: 2003-05-31Updated: 2013-06-20